Successful guidewire crossing via collateral channel at retrograde percutaneous coronary intervention for chronic total occlusion: the J-Channel score.
逆行经皮冠状动脉介入治疗慢性完全闭塞时成功的导丝通过侧支通道: J 通道评分。
- 作者列表："Nagamatsu W","Tsuchikane E","Oikawa Y","Sumitsuji S","Igarashi Y","Yoshikawa R","Muto M","Okada H","Katoh O
AIMS:Guidewire (GW) tracking in a collateral channel (CC) is an important step during retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI). The aim of this study was to create a prediction score model for CC GW crossing success. METHODS AND RESULTS:We analysed data on 886 CCs included in the Japanese CTO PCI Expert Registry during 2016. CCs were categorised as septal (n=610) and non-septal (n=276). CCs were randomly assigned to derivation and validation sets in a 2:1 ratio. The score was developed by multivariate analysis with angiographic findings. Small vessel, reverse bend, and continuous bends were independent predictors in the septal CC subset. Small vessel, reverse bend, and corkscrew were independent predictors in the non-septal CC subset. The extent of intervention was easy, intermediate, and difficult in 92.9%, 57.4%, and 16.7% in the septal CC subset and 91.7%, 54.3%, and 19.0% in the non-septal CC subset, respectively, in the validation set. The area under the receiver operating characteristic curve was >0.7 in the derivation and validation sets of both CC subsets. CONCLUSIONS:The prediction score model can suggest grading of the difficulty of CC GW crossing based on angiographic findings for each type of CC.
目的: 侧支通道 (CC) 的导丝 (GW) 追踪是逆行慢性完全闭塞 (CTO) 经皮冠状动脉介入治疗 (PCI) 的重要步骤。本研究的目的是创建 CC GW 穿越成功的预测评分模型。 方法和结果: 我们分析了 2016年日本 CTO PCI 专家登记处纳入的 886 个 CCs 的数据。CCs 分为间隔 (n = 610) 和非间隔 (n = 276)。CCs 以 2:1 的比例随机分配到推导和验证集。通过血管造影结果的多变量分析制定评分。小血管、反向弯曲和连续弯曲是间隔 CC 子集的独立预测因素。小血管、反向弯曲和螺旋体是非间隔 CC 子集的独立预测因素。干预范围在间隔 CC 子集的 92.9% 、 57.4% 和 16.7% 以及在非间隔 CC 子集的 91.7% 、 54.3% 和 19.0% 中分别为容易、中间和困难。在验证集中。在两个 CC 子集的推导和验证集中，受试者工作特征曲线下面积> 0.7。 结论: 预测评分模型可以根据每种类型 CC 的血管造影结果提示 CC GW 交叉的难度分级。
METHODS:Aims : We sought to investigate the thrombogenicity of different DES and BMS in an in vitro system of stent perfusion. Material and Methods: The experimental model consisted of a peristaltic pump connected to 4 parallel silicone tubes in which different stents were deployed. Blood was drawn from healthy volunteers and the amount of stent surfaced -induced thrombus deposition was determined using 125 I -fibrinogen. Results: Compared to Resolute, Biomatrix and Vision, Xience was associated with the lowest amount of stent surface -induced thrombus formation, with a significant difference compared to Vision (125 I -fibrinogen median value deposition [IQ range]: 50 ng [25 -98] versus 560 ng [320 - 1,520], respectively, p<0.05), but not to other DES. In the second set of experiments Fluoropolymer -coated BMS not eluting drug was associated with a significant 3 -fold reduction in 125 I -fibrinogen deposition (245 ng [80 -300]) compared to Vision (625 ng [320 -760], p<0.05), but a 7 -fold increase compared to Xience (35 ng [20 -60], p<0.05). Finally Xience was associated with a significantly greater absorption of albumin compared to BMS. Conclusions: In an in vitro system of stent perfusion, Xience was associated with the lowest amount of stent surface -induced thrombus formation compared with Resolute, Biomatrix and Vision, with a noted synergistic effect between the fluoropolymer and the drug.
METHODS::Fibronectin-splice variant containing extra domain A (Fn-EDA) is associated with smooth muscle cells (SMCs) following vascular injury. The role of SMC-derived Fn-EDA in SMC phenotypic switching or its implication in neointimal hyperplasia remains unclear. Herein, using human coronary artery sections with a bare metal stent, we demonstrate the expression of Fn-EDA in the vicinity of SMC-rich neointima and peri-strut areas. In mice, Fn-EDA colocalizes with SMCs in the neointima of injured carotid arteries and promotes neointima formation in the comorbid condition of hyperlipidemia by potentiating SMC proliferation and migration. No sex-based differences were observed. Mechanistic studies suggested that Fn-EDA mediates integrin- and TLR4-dependent proliferation and migration through activation of FAK/Src and Akt1/mTOR signaling, respectively. Specific deletion of Fn-EDA in SMCs, but not in endothelial cells, reduced intimal hyperplasia and suppressed the SMC synthetic phenotype concomitant with decreased Akt1/mTOR signaling. Targeting Fn-EDA in human aortic SMCs suppressed the synthetic phenotype and downregulated Akt1/mTOR signaling. These results reveal that SMC-derived Fn-EDA potentiates phenotypic switching in human and mouse aortic SMCs and neointimal hyperplasia in the mouse. We suggest that targeting Fn-EDA could be explored as a potential therapeutic strategy to reduce neointimal hyperplasia.
METHODS:OBJECTIVE:The goal of this study was to determine the impact of late-acquired stent malapposition (LASM) on long-term clinical outcomes in patients treated with coronary stent implantation. Approach and Results: We investigated major adverse cardiac event during 10 years after 6-month intravascular ultrasound examination using our previous studies database. A total of 732 patients treated with bare-metal stent (54 LASM versus 678 non-LASM) and 529 patients treated with first-generation drug-eluting stent (82 LASM versus 447 non-LASM), who did not have clinical event or censoring at the time of follow-up intravascular ultrasound, were included for the present analysis. major adverse cardiac event was defined as the composite of cardiac death, target vessel-related myocardial infarction, target lesion revascularization and stent thrombosis. Multivariable adjustment and inverse probability weight were performed to consider baseline differences. After multivariable adjustment, LASM was related to a greater risk of major adverse cardiac event (hazard ratio, 1.666 [95% CI, 1.041-2.665]; P=0.0333) and very-late stent thrombosis (hazard ratio, 3.529 [95% CI, 1.153-10.798]; P=0.0271) than non-LASM in patients treated with first-generation drug-eluting stent, but not in those treated with bare-metal stent. Results were consistent after inverse probability weight. Among patients with LASM of first-generation drug-eluting stent, no late stent thrombosis occurred in patients who continued to receive dual antiplatelet therapy. CONCLUSIONS:The relationship between LASM and major adverse cardiac event might depend on the type of implanted stents during the long-term follow-up, highlighting the clinical significance of polymers and drugs in drug-eluting stent system.